108 related articles for article (PubMed ID: 7885431)
1. Gene therapy approval may be rocky road for industry.
Gavaghan H
Nature; 1995 Mar; 374(6519):202. PubMed ID: 7885431
[No Abstract] [Full Text] [Related]
2. RAC defers to NIH director on some gene therapy cases.
Gershon D
Nature; 1993 Jan; 361(6409):196. PubMed ID: 8423842
[No Abstract] [Full Text] [Related]
3. NIH under fire over gene-therapy trials..
Wadman M
Nature; 2000 Jan; 403(6767):237. PubMed ID: 10659820
[No Abstract] [Full Text] [Related]
4. Gene advisory group switches focus to ethical issues.
Gavaghan H
Nature; 1994 Oct; 371(6497):468. PubMed ID: 7935752
[No Abstract] [Full Text] [Related]
5. Lentiviral vectors approach the clinic but fall back: National Institutes of Health Recombinant DNA Advisory Committee review of a first clinical protocol for use of a lentiviral vector.
Podsakoff GM
Mol Ther; 2001 Oct; 4(4):282-3. PubMed ID: 11592827
[No Abstract] [Full Text] [Related]
6. NIH review to suggest streamlined handling of gene therapy bids.
Taylor R
Nature; 1995 Jun; 375(6534):713. PubMed ID: 7596397
[No Abstract] [Full Text] [Related]
7. Cracks in the RAC.
Gershon D
Nature; 1991 Oct; 353(6345):591. PubMed ID: 1922377
[No Abstract] [Full Text] [Related]
8. Federal agency keeps review committee after public comments support continuation.
Maloney DM
Hum Res Rep; 1997 Jan; 12(1):1-2. PubMed ID: 11654603
[No Abstract] [Full Text] [Related]
9. Gene therapy panel gets a thumbs up.
Science; 1995 Nov; 270(5240):1287. PubMed ID: 11644754
[No Abstract] [Full Text] [Related]
10. Gene therapy on trial.
Marshall E
Science; 2000 May; 288(5468):951-7. PubMed ID: 10841710
[No Abstract] [Full Text] [Related]
11. Review panel cancels meeting as gene therapy proposals fall.
Wadman M
Nature; 1996 Feb; 379(6567):668. PubMed ID: 11644770
[No Abstract] [Full Text] [Related]
12. Special informed consent requirements are included in protocol review procedures.
Maloney DM
Hum Res Rep; 1995 Jul; 10(7):1-2. PubMed ID: 11654274
[No Abstract] [Full Text] [Related]
13. New rules for gene-transfer trials.
Nelson RM
IRB; 2001; 23(6):11. PubMed ID: 12737176
[No Abstract] [Full Text] [Related]
14. Gene panel reprieved after public outcry..
Wadman M
Nature; 1996 Nov; 384(6607):297. PubMed ID: 8934501
[No Abstract] [Full Text] [Related]
15. Gene therapy investigations proliferate.
Hollon T
Nat Med; 2000 Mar; 6(3):235. PubMed ID: 10700200
[No Abstract] [Full Text] [Related]
16. Toward a more comprehensive approach to protecting human subjects: the interface of data safety monitoring boards and institutional review boards in randomized clinical trials.
Gordon VM; Sugarman J; Kass N
IRB; 1998; 20(1):1-5. PubMed ID: 11655324
[No Abstract] [Full Text] [Related]
17. Light, fast, and flexible: a new approach to regulation of human gene therapy.
Cregan JA
McGeorge Law Rev; 2000; 32(1):261-87. PubMed ID: 15709266
[No Abstract] [Full Text] [Related]
18. Orkin-Motulsky panel calls for gene therapy basic research.
Fox JL
Gene Ther; 1996 Jan; 3(1):pre-1. PubMed ID: 11644882
[No Abstract] [Full Text] [Related]
19. Government regulation of human gene therapy.
Gage JL
Jurimetrics; 1987; 27(2):200-18. PubMed ID: 11651978
[No Abstract] [Full Text] [Related]
20. Regulation of human gene therapy.
Chase GA; DeLeon PA; Dronamraju KR; Erickson RP; Glorioso JC; Hirschhorn R; Lysaught MT; McGraw KM; Meyers AS; Miller AD
Science; 1995 Jul; 269(5220):14-5. PubMed ID: 7604272
[No Abstract] [Full Text] [Related]
[Next] [New Search]
